Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey

References

• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005;20:479-82
   PubMed Web of Science ®Google Scholar
• Jenkins N, Hallowell N, Farmer AJ, et al. Participants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study. Diabet Med 2011;28:543-8
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Davies MJ, Gagliardino JJ, Gray LJ, et al. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med 2013;30:512-24
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010;4(1 Suppl):S11-18
   Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-50
   PubMed Web of Science ®Google Scholar
• Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350:1505-10
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35:S11-63
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Guidelines for management of postmeal glucose. 2012. http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes. Accessed August 8, 2012
   Google Scholar
• Yeaw J, Lee WC, Wolden ML, et al. Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes. Diabetes Ther 2012;3:7
   PubMedGoogle Scholar
• Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
   PubMed Web of Science ®Google Scholar
• Liebl A, Breitscheidel L, Nicolay C, et al. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008;24:2349-58
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
   PubMed Web of Science ®Google Scholar
• Dolan P. Modelling valuations for health states: the effect of duration. Health Policy 1996;38:189-203
   PubMed Web of Science ®Google Scholar
• Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;6:73
   PubMed Web of Science ®Google Scholar
• Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res 2002;2:99-108
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. 2013. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed Oct 01 2013
   Google Scholar
• Scottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). 2013. http://www.scottishmedicines.org.uk/Submission_Process/Submission_Guidance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed August 25, 2013
   Google Scholar
• CADTH. HTA Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edn. 2006. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed August 25, 2013
   Google Scholar
• TLV (the Dental and Pharmaceutical Benefits Agency in Sweden). 2003. Läkemedelsförmånsnämndens allmänna råd. Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar. http://www.tlv.se/Upload/Lagar_och_foreskrifter/LAG-lfnar-2003-2.pdf. Accessed August 25, 2013
   Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO life tables. 2013. http://www.who.int/gho/mortality_burden_disease/life_tables/life_tables/en/. Accessed Oct 01 2013
   Google Scholar
• Dolan P. The measurement of health-related quality of life for use in resource allocation decisions in health care. In: Culyer AJ, Newhouse JP, eds. Handbook of Health Economics. Amsterdam: Elsevier Science BV, 2000. p 1738-40
   Google Scholar
• Gold MR, Siegal JE, Rutten GE, et al. Identifying and valuing outcomes. In: Gold MR, Siegal JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996. p 105-6
   Google Scholar
• Hurley J. An overview of the normative economics of the health sector. In: Gold MR, Siegal JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
   Google Scholar
• Atkinson SE, Wilson PW. Comparing mean efficiency and productivity scores from small samples: a bootstrap methodology. J Prod Anal 1995;6:137-52
   Web of Science ®Google Scholar
• Kotsanos JG, Vignati L, Huster W, et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 1997;20:948-58
   PubMed Web of Science ®Google Scholar
• Randlöv J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin A1c in people with diabetes? A simulation study. J Diabetes Sci Technol 2008;2:229-35
   PubMedGoogle Scholar
• Farmer AJ, Wade AN, French DP, et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess 2009;13:iii-xi, 1
   PubMed Web of Science ®Google Scholar
• Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-80
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
   PubMed Web of Science ®Google Scholar
• Ekman A, Dickman PW, Klint A, et al. Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur J Epidemiol 2006;21:103-11
   PubMed Web of Science ®Google Scholar
• Lund E, Gram IT. Response rate according to title and length of questionnaire. Scand J Soc Med 1998;26:154-60
   PubMedGoogle Scholar
• van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;172:1292-8
   PubMed Web of Science ®Google Scholar